Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
Last Updated: Monday, November 22, 2021
An analysis of tumor biopsy samples from the phase 3 PHOENIX trial suggests that younger patients (≤ 60 years) with either MCD or N1 subtype non-GCB DLBCL derive a survival benefit from combination treatment with ibrutinib and R-CHOP chemotherapy. Three-year event-free survival was 100% for both subtypes of patients treated with the combination, compared with 42.9% and 50% in the MCD and N1 subtypes, respectively, treated with R-CHOP alone.
Advertisement
News & Literature Highlights
